Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03195868 · ClinicalTrials.gov registry record · NA

Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

A NA study, sponsored by University of Minnesota.

Completed
Registry status
NA
Development phase
70
Enrollment target

NCT03195868 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 70 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03195868, a NA study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target

Study Summary

This study seeks to determine if photobiomodulation (PBM, or low level laser light) affects the growth and distribution of nerves int he skin. Our previous study demonstrated that the treatment we use here was effective at reducing the symptoms of neuropathy (as measured by the modified total neuropathy score) in patients who had been treated with chemotherapy. The current effort is designed to repeat this confirm this observation using a more extensive battery of survey as well as to begin to elucidate the mechanism through which photobiomodulaiton produces the effect. WE will also be attempting to determine if diabetic patients differ in terms of response from chemotherapy patients

Interventions

  • DEVICE Realief Therapy

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2019-09-30
Est. Completion 2021-01-21
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT03195868

The ClinicalTrials.gov registry entry for NCT03195868 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Realief Therapy is the first listed.

NCT03195868 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03195868 about?

NCT03195868 is a clinical study titled "Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy". This study seeks to determine if photobiomodulation (PBM, or low level laser light) affects the growth and distribution of nerves int he skin. Our previous study demonstrated that the treatment we use here was effective at reducing the symptoms of neuropathy (as measured by the modified total neurop...

What is the current status of trial NCT03195868?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2019-09-30. Estimated completion is 2021-01-21.

What interventions are being tested in trial NCT03195868?

The interventions under investigation include: Realief Therapy (DEVICE).

Who is sponsoring clinical trial NCT03195868?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.